|Bid||0.00 x 0|
|Ask||0.00 x 0|
|Day's range||317.15 - 324.50|
|52-week range||302.40 - 404.20|
|Beta (5Y monthly)||0.31|
|PE ratio (TTM)||19.90|
|Forward dividend & yield||9.30 (2.92%)|
|Ex-dividend date||17 Mar 2022|
|1y target est||N/A|
Pfizer (PFE) is set to buy migraine drugmaker, Biohaven Pharmaceuticals for $11.6 billion. Bayer (BAYRY) beats Q1 earnings and sales expectations.
Roche (RHHBY) stock declines as the late-stage study evaluating tiragolumab plus Tecentriq fails to meet its co-primary endpoint of progression-free survival.
Epizyme (EPZM) posts a wider-than-expected loss for the first quarter. Revenues also miss estimates. EPZM has multiple pipeline readouts on track for this year.